Literature DB >> 12097810

Effects of the hallucinogen psilocybin on covert orienting of visual attention in humans.

E Gouzoulis-Mayfrank1, B Thelen, S Maier, K Heekeren, K-A Kovar, H Sass, M Spitzer.   

Abstract

Hallucinogenic drug-induced states are considered as models for acute schizophrenic disorders (experimental psychoses). In a double-blind study with healthy volunteers we investigated the influence of the serotonergic hallucinogen psilocybin, the ecstasy-like drug 3,4-methylenedioxyethylamphetamine (MDE), the stimulant d- methamphetamine and placebo on covert orienting of spatial attention (n = 8 in each group). Reaction times were prolonged after ingestion of psilocybin > MDE, but not after d-methamphetamine. In addition, subjects on psilocybin exhibited particularly slow reaction times in invalid trials at short cue target intervals and failure of response inhibition in valid trials at long cue target intervals for right visual field targets. Despite some methodological limitations, these results are in line with both bilateral impairment of disengagement of attention and a lateralized impairment of inhibition of return (IOR) in productive psychotic states. Additional investigations with larger samples, different hallucinogenic substances (serotonergic agonists vs. NMDA antagonists) and different dose regimens are needed in order to further explore the suggested relationship between visuospatial attentional dysfunction and acute psychotic conditions. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12097810     DOI: 10.1159/000063672

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  9 in total

1.  Effects of ayahuasca on binocular rivalry with dichoptic stimulus alternation.

Authors:  E Frecska; K D White; L E Luna
Journal:  Psychopharmacology (Berl)       Date:  2004-01-08       Impact factor: 4.530

2.  Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers.

Authors:  Boris B Quednow; Michael Kometer; Mark A Geyer; Franz X Vollenweider
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 3.  On the measurement of the effects of alcohol and illicit substances on inhibition of return.

Authors:  Janine V Olthuis; Raymond M Klein
Journal:  Psychopharmacology (Berl)       Date:  2012-05-09       Impact factor: 4.530

4.  Acute effects of ayahuasca on neuropsychological performance: differences in executive function between experienced and occasional users.

Authors:  José Carlos Bouso; Josep Maria Fábregas; Rosa Maria Antonijoan; Antoni Rodríguez-Fornells; Jordi Riba
Journal:  Psychopharmacology (Berl)       Date:  2013-06-21       Impact factor: 4.530

Review 5.  Human hallucinogen research: guidelines for safety.

Authors:  Mw Johnson; Wa Richards; Rr Griffiths
Journal:  J Psychopharmacol       Date:  2008-07-01       Impact factor: 4.153

6.  Neuropscyhological Complications of HIV Disease and Substances of Abuse.

Authors:  Lisa R Norman; Anil Kumar
Journal:  Am J Infect Dis       Date:  2006

7.  The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions.

Authors:  André Schmidt; Michael Kometer; Rosilla Bachmann; Erich Seifritz; Franz Vollenweider
Journal:  Psychopharmacology (Berl)       Date:  2012-07-27       Impact factor: 4.530

8.  A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review.

Authors:  Niloufar Pouyan; Zahra Halvaei Khankahdani; Farnaz Younesi Sisi; Yena Lee; Joshua D Rosenblat; Kayla M Teopiz; Leanna M W Lui; Mehala Subramaniapillai; Kangguang Lin; Flora Nasri; Nelson Rodrigues; Hartej Gill; Orly Lipsitz; Bing Cao; Roger Ho; David Castle; Roger S McIntyre
Journal:  CNS Drugs       Date:  2022-09-12       Impact factor: 6.497

9.  Dimensions of consciousness and the psychedelic state.

Authors:  Tim Bayne; Olivia Carter
Journal:  Neurosci Conscious       Date:  2018-09-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.